<?xml version="1.0" encoding="UTF-8"?>
<p>The 1176 study subjects were allocated to a no-treatment group (n = 687) or a treatment group (n = 489). Patients in the treatment group were treated with PEG-IFN (alfa-2a or alfa-2b)/RBV for 24 or 48 weeks according to HCV genotype, and allocated to 1 of 2 subgroups dependent on the achievement of SVR (the SVR (+) and SVR (−) subgroups) after PEG-IFN/RBV treatment (Fig. 
 <xref ref-type="fig" rid="F1">1</xref>). The study was approved by the Institutional Review Board of Inha University Hospital, Incheon, South Korea (approval number: INHAUH 2015-11-018).
</p>
